NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









OrbiMed

OrbiMed

New York City, New Yorkorbimed.com

Overview

OrbiMed is a global investment firm that invests in companies engaged in the discovery and development of biopharmaceutical products, medical technologies, medical devices, diagnostics, drug discovery tools, and healthcare information technology and services companies.

Year Founded

1989

AUM

$17B

Portfolio Companies

283

Investments

OrbiMed investments
CompanyDateStageLead
TytoCareJul 2026Growth EquityCo-investor
Iswarya Fertility Centre & Women's HospitalJul 2026Growth EquityLead
IshvaramJul 2026VC RoundLead
Fore BiotherapeuticsJul 2026Series D-2 ExtensionCo-investor
Lycia TherapeuticsJun 2026Series DCo-investor

Key People

Sam Isaly

Founder And Chairman Emeritus

Carl Gordon

Managing Partner

Carter Neild

Managing Partner

Jonathan Silverstein

Former Co-Head of Private Equity and Managing Partner Currently an Executive Partner

Sven H. Borho

Managing Partner

David Bonita

General Partner

Geoffrey Hsu

General Partner

Matthew Rizzo

General Partner

David Wang

Partner, Senior Managing Director, Asia

Anat Nursella

Venture Partner

Bob Smith

Venture Partner

Dimitri Krainc

Venture Partner

Donnie McGrath

Venture Partner

Iain Dukes

Venture Partner

James Christensen

Venture Partner

Jeff Peters

Venture Partner

Sector & Stage Mix

Industry, funding stage, and valuation band breakdowns.

Premium
SeedSeries ASeries BGrowth

Unlock portfolio analytics

Sign up to view full sector, stage, and valuation breakdowns for this investor.

Investment Activity

Yearly cadence, pace, and funding raised over time.

Premium
2021
2022
2023
2024
2025
2026

Unlock portfolio analytics

Sign up to explore yearly investment trends and funding raised over time.

FAQ

Firmographic Details

HeadquartersNew York City, New York
Year Founded1989
AUM$17B

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.